Prognostic implication of mucinous histology in colorectal cancer patients treated with adjuvant FOLFOX chemotherapy
Background: There have been controversies in prognostic impact of mucinous histology on colorectal cancer, and its implication in patients treated with adjuvant 5-fluorouracil, leucovorin, and oxaliplatin (FOLFOX) is unclear. Methods: Stage II and III colorectal cancer patients who underwent curativ...
Gespeichert in:
| Veröffentlicht in: | British journal of cancer 2013-05, Vol.108 (10), p.1978-1984 |
|---|---|
| Hauptverfasser: | , , , , , , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 1984 |
|---|---|
| container_issue | 10 |
| container_start_page | 1978 |
| container_title | British journal of cancer |
| container_volume | 108 |
| creator | Lee, D-W Han, S-W Lee, H J Rhee, Y-Y Bae, J M Cho, N-Y Lee, K-H Kim, T-Y Oh, D-Y Im, S-A Bang, Y-J Jeong, S-Y Park, K J Park, J-G Kang, G H Kim, T-Y |
| description | Background:
There have been controversies in prognostic impact of mucinous histology on colorectal cancer, and its implication in patients treated with adjuvant 5-fluorouracil, leucovorin, and oxaliplatin (FOLFOX) is unclear.
Methods:
Stage II and III colorectal cancer patients who underwent curative resection followed by adjuvant FOLFOX were included. Patients were grouped according to the mucinous content: >50%, mucinous adenocarcinoma (MAC); |
| doi_str_mv | 10.1038/bjc.2013.232 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_3670503</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2981885311</sourcerecordid><originalsourceid>FETCH-LOGICAL-c480t-52c8c6e2a938a1123f4c070bfe32066db9acfbb12bba28e63b142a0bade42df73</originalsourceid><addsrcrecordid>eNptkc2LFDEQxYMo7rh68ywB8WaPlaQ_L4IsjgoD40HBW6ik09MZupMxSa_Mf2-WGdcVPKVC_erVox4hLxmsGYj2nTroNQcm1lzwR2TFKsEL1vLmMVkBQFNAx-GKPIvxkL8dtM1TcsVFXXHBYEXS1-D3zsdkNbXzcbIak_WO-oHOi7bOL5GONiY_-f2JWkd1roLRCSeq0WkT6DFPGJciTcFgMj39ZdNIsT8st-gS3ey2m90Pqkcz-zSagMfTc_JkwCmaF5f3mnzffPx287nY7j59ufmwLXTZQioqrltdG46daJExLoZSQwNqMIJDXfeqQz0oxbhSyFtTC8VKjqCwNyXvh0Zck_dn3eOiZtPr7DLgJI_BzhhO0qOV_3acHeXe30pRN1CByAKvLwLB_1xMTPLgl-CyZ8lEVbWdgLrM1NszpYOPMZjhfgMDeZeRzBnJu4xkzijjrx66uof_hJKBNxcAo8ZpCPnONv7lGtFB13WZK85czC23N-GBu_8t_g0UyKx3</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1355893064</pqid></control><display><type>article</type><title>Prognostic implication of mucinous histology in colorectal cancer patients treated with adjuvant FOLFOX chemotherapy</title><source>MEDLINE</source><source>SpringerLink Journals</source><source>Nature Journals Online</source><source>Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals</source><source>PubMed Central</source><creator>Lee, D-W ; Han, S-W ; Lee, H J ; Rhee, Y-Y ; Bae, J M ; Cho, N-Y ; Lee, K-H ; Kim, T-Y ; Oh, D-Y ; Im, S-A ; Bang, Y-J ; Jeong, S-Y ; Park, K J ; Park, J-G ; Kang, G H ; Kim, T-Y</creator><creatorcontrib>Lee, D-W ; Han, S-W ; Lee, H J ; Rhee, Y-Y ; Bae, J M ; Cho, N-Y ; Lee, K-H ; Kim, T-Y ; Oh, D-Y ; Im, S-A ; Bang, Y-J ; Jeong, S-Y ; Park, K J ; Park, J-G ; Kang, G H ; Kim, T-Y</creatorcontrib><description>Background:
There have been controversies in prognostic impact of mucinous histology on colorectal cancer, and its implication in patients treated with adjuvant 5-fluorouracil, leucovorin, and oxaliplatin (FOLFOX) is unclear.
Methods:
Stage II and III colorectal cancer patients who underwent curative resection followed by adjuvant FOLFOX were included. Patients were grouped according to the mucinous content: >50%, mucinous adenocarcinoma (MAC); <50%, adenocarcinoma with intermediated mucinous component (AIM); and without any mucinous component, non-MAC (NMA). Clinicopathological features and disease-free survival (DFS) were compared.
Results:
Among a total of 521 patients, 27 patients (5.2%) had MAC, 41 patients (7.9%) had AIM, and 453 patients (86.9%) had NMA. Mucinous adenocarcinoma and AIM had higher frequency of proximal location and microsatellite instability, but lower frequency of angiolymphatic invasion. Disease-free survival was significantly worse in the MAC compared with NMA (3-year DFS 57% and 86%, respectively;
P
<0.001) and AIM (3-year DFS 87%,
P
=0.01
vs
MAC). Multivariate analysis revealed MAC as an independent negative prognostic factor of DFS (adjusted hazard ratio 7.96, 95% confidence interval 3.76–16.8).
Conclusion:
Adenocarcinoma with intermediated mucinous component and MAC have distinct clinicopathological features compared with NMA. Mucinous adenocarcinoma has an adverse prognostic impact on stage II or III colorectal cancer treated with adjuvant FOLFOX.</description><identifier>ISSN: 0007-0920</identifier><identifier>EISSN: 1532-1827</identifier><identifier>DOI: 10.1038/bjc.2013.232</identifier><identifier>PMID: 23652310</identifier><identifier>CODEN: BJCAAI</identifier><language>eng</language><publisher>London: Nature Publishing Group UK</publisher><subject>692/699/67/1059/99 ; 692/699/67/1504/1885 ; 692/700/1750 ; Adenocarcinoma, Mucinous - drug therapy ; Adenocarcinoma, Mucinous - pathology ; Adult ; Aged ; Aged, 80 and over ; Antineoplastic Combined Chemotherapy Protocols - therapeutic use ; Biological and medical sciences ; Biomedical and Life Sciences ; Biomedicine ; Cancer Research ; Cancer therapies ; Chemotherapy ; Chemotherapy, Adjuvant ; Clinical Study ; Colorectal cancer ; Colorectal Neoplasms - drug therapy ; Colorectal Neoplasms - pathology ; Drug Resistance ; Epidemiology ; Female ; Fluorouracil - therapeutic use ; Gastroenterology. Liver. Pancreas. Abdomen ; Histology ; Hospitals ; Humans ; Leucovorin - therapeutic use ; Male ; Medical research ; Medical sciences ; Medicine ; Middle Aged ; Molecular Medicine ; Mucins - analysis ; Mucins - metabolism ; Multiple tumors. Solid tumors. Tumors in childhood (general aspects) ; Neoplasm Staging ; Oncology ; Organoplatinum Compounds - therapeutic use ; Patients ; Prognosis ; Retrospective Studies ; Stomach. Duodenum. Small intestine. Colon. Rectum. Anus ; Tomography ; Tumors</subject><ispartof>British journal of cancer, 2013-05, Vol.108 (10), p.1978-1984</ispartof><rights>The Author(s) 2013</rights><rights>2014 INIST-CNRS</rights><rights>Copyright Nature Publishing Group May 28, 2013</rights><rights>Copyright © 2013 Cancer Research UK 2013 Cancer Research UK</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c480t-52c8c6e2a938a1123f4c070bfe32066db9acfbb12bba28e63b142a0bade42df73</citedby><cites>FETCH-LOGICAL-c480t-52c8c6e2a938a1123f4c070bfe32066db9acfbb12bba28e63b142a0bade42df73</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC3670503/pdf/$$EPDF$$P50$$Gpubmedcentral$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC3670503/$$EHTML$$P50$$Gpubmedcentral$$Hfree_for_read</linktohtml><link.rule.ids>230,314,723,776,780,881,27901,27902,41464,42533,51294,53766,53768</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=27390999$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/23652310$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Lee, D-W</creatorcontrib><creatorcontrib>Han, S-W</creatorcontrib><creatorcontrib>Lee, H J</creatorcontrib><creatorcontrib>Rhee, Y-Y</creatorcontrib><creatorcontrib>Bae, J M</creatorcontrib><creatorcontrib>Cho, N-Y</creatorcontrib><creatorcontrib>Lee, K-H</creatorcontrib><creatorcontrib>Kim, T-Y</creatorcontrib><creatorcontrib>Oh, D-Y</creatorcontrib><creatorcontrib>Im, S-A</creatorcontrib><creatorcontrib>Bang, Y-J</creatorcontrib><creatorcontrib>Jeong, S-Y</creatorcontrib><creatorcontrib>Park, K J</creatorcontrib><creatorcontrib>Park, J-G</creatorcontrib><creatorcontrib>Kang, G H</creatorcontrib><creatorcontrib>Kim, T-Y</creatorcontrib><title>Prognostic implication of mucinous histology in colorectal cancer patients treated with adjuvant FOLFOX chemotherapy</title><title>British journal of cancer</title><addtitle>Br J Cancer</addtitle><addtitle>Br J Cancer</addtitle><description>Background:
There have been controversies in prognostic impact of mucinous histology on colorectal cancer, and its implication in patients treated with adjuvant 5-fluorouracil, leucovorin, and oxaliplatin (FOLFOX) is unclear.
Methods:
Stage II and III colorectal cancer patients who underwent curative resection followed by adjuvant FOLFOX were included. Patients were grouped according to the mucinous content: >50%, mucinous adenocarcinoma (MAC); <50%, adenocarcinoma with intermediated mucinous component (AIM); and without any mucinous component, non-MAC (NMA). Clinicopathological features and disease-free survival (DFS) were compared.
Results:
Among a total of 521 patients, 27 patients (5.2%) had MAC, 41 patients (7.9%) had AIM, and 453 patients (86.9%) had NMA. Mucinous adenocarcinoma and AIM had higher frequency of proximal location and microsatellite instability, but lower frequency of angiolymphatic invasion. Disease-free survival was significantly worse in the MAC compared with NMA (3-year DFS 57% and 86%, respectively;
P
<0.001) and AIM (3-year DFS 87%,
P
=0.01
vs
MAC). Multivariate analysis revealed MAC as an independent negative prognostic factor of DFS (adjusted hazard ratio 7.96, 95% confidence interval 3.76–16.8).
Conclusion:
Adenocarcinoma with intermediated mucinous component and MAC have distinct clinicopathological features compared with NMA. Mucinous adenocarcinoma has an adverse prognostic impact on stage II or III colorectal cancer treated with adjuvant FOLFOX.</description><subject>692/699/67/1059/99</subject><subject>692/699/67/1504/1885</subject><subject>692/700/1750</subject><subject>Adenocarcinoma, Mucinous - drug therapy</subject><subject>Adenocarcinoma, Mucinous - pathology</subject><subject>Adult</subject><subject>Aged</subject><subject>Aged, 80 and over</subject><subject>Antineoplastic Combined Chemotherapy Protocols - therapeutic use</subject><subject>Biological and medical sciences</subject><subject>Biomedical and Life Sciences</subject><subject>Biomedicine</subject><subject>Cancer Research</subject><subject>Cancer therapies</subject><subject>Chemotherapy</subject><subject>Chemotherapy, Adjuvant</subject><subject>Clinical Study</subject><subject>Colorectal cancer</subject><subject>Colorectal Neoplasms - drug therapy</subject><subject>Colorectal Neoplasms - pathology</subject><subject>Drug Resistance</subject><subject>Epidemiology</subject><subject>Female</subject><subject>Fluorouracil - therapeutic use</subject><subject>Gastroenterology. Liver. Pancreas. Abdomen</subject><subject>Histology</subject><subject>Hospitals</subject><subject>Humans</subject><subject>Leucovorin - therapeutic use</subject><subject>Male</subject><subject>Medical research</subject><subject>Medical sciences</subject><subject>Medicine</subject><subject>Middle Aged</subject><subject>Molecular Medicine</subject><subject>Mucins - analysis</subject><subject>Mucins - metabolism</subject><subject>Multiple tumors. Solid tumors. Tumors in childhood (general aspects)</subject><subject>Neoplasm Staging</subject><subject>Oncology</subject><subject>Organoplatinum Compounds - therapeutic use</subject><subject>Patients</subject><subject>Prognosis</subject><subject>Retrospective Studies</subject><subject>Stomach. Duodenum. Small intestine. Colon. Rectum. Anus</subject><subject>Tomography</subject><subject>Tumors</subject><issn>0007-0920</issn><issn>1532-1827</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2013</creationdate><recordtype>article</recordtype><sourceid>C6C</sourceid><sourceid>EIF</sourceid><sourceid>BENPR</sourceid><recordid>eNptkc2LFDEQxYMo7rh68ywB8WaPlaQ_L4IsjgoD40HBW6ik09MZupMxSa_Mf2-WGdcVPKVC_erVox4hLxmsGYj2nTroNQcm1lzwR2TFKsEL1vLmMVkBQFNAx-GKPIvxkL8dtM1TcsVFXXHBYEXS1-D3zsdkNbXzcbIak_WO-oHOi7bOL5GONiY_-f2JWkd1roLRCSeq0WkT6DFPGJciTcFgMj39ZdNIsT8st-gS3ey2m90Pqkcz-zSagMfTc_JkwCmaF5f3mnzffPx287nY7j59ufmwLXTZQioqrltdG46daJExLoZSQwNqMIJDXfeqQz0oxbhSyFtTC8VKjqCwNyXvh0Zck_dn3eOiZtPr7DLgJI_BzhhO0qOV_3acHeXe30pRN1CByAKvLwLB_1xMTPLgl-CyZ8lEVbWdgLrM1NszpYOPMZjhfgMDeZeRzBnJu4xkzijjrx66uof_hJKBNxcAo8ZpCPnONv7lGtFB13WZK85czC23N-GBu_8t_g0UyKx3</recordid><startdate>20130528</startdate><enddate>20130528</enddate><creator>Lee, D-W</creator><creator>Han, S-W</creator><creator>Lee, H J</creator><creator>Rhee, Y-Y</creator><creator>Bae, J M</creator><creator>Cho, N-Y</creator><creator>Lee, K-H</creator><creator>Kim, T-Y</creator><creator>Oh, D-Y</creator><creator>Im, S-A</creator><creator>Bang, Y-J</creator><creator>Jeong, S-Y</creator><creator>Park, K J</creator><creator>Park, J-G</creator><creator>Kang, G H</creator><creator>Kim, T-Y</creator><general>Nature Publishing Group UK</general><general>Nature Publishing Group</general><scope>C6C</scope><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7RV</scope><scope>7TO</scope><scope>7U9</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8AO</scope><scope>8C1</scope><scope>8FE</scope><scope>8FH</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AN0</scope><scope>AZQEC</scope><scope>BBNVY</scope><scope>BENPR</scope><scope>BHPHI</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>H94</scope><scope>HCIFZ</scope><scope>K9.</scope><scope>KB0</scope><scope>LK8</scope><scope>M0S</scope><scope>M1P</scope><scope>M7P</scope><scope>NAPCQ</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>5PM</scope></search><sort><creationdate>20130528</creationdate><title>Prognostic implication of mucinous histology in colorectal cancer patients treated with adjuvant FOLFOX chemotherapy</title><author>Lee, D-W ; Han, S-W ; Lee, H J ; Rhee, Y-Y ; Bae, J M ; Cho, N-Y ; Lee, K-H ; Kim, T-Y ; Oh, D-Y ; Im, S-A ; Bang, Y-J ; Jeong, S-Y ; Park, K J ; Park, J-G ; Kang, G H ; Kim, T-Y</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c480t-52c8c6e2a938a1123f4c070bfe32066db9acfbb12bba28e63b142a0bade42df73</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2013</creationdate><topic>692/699/67/1059/99</topic><topic>692/699/67/1504/1885</topic><topic>692/700/1750</topic><topic>Adenocarcinoma, Mucinous - drug therapy</topic><topic>Adenocarcinoma, Mucinous - pathology</topic><topic>Adult</topic><topic>Aged</topic><topic>Aged, 80 and over</topic><topic>Antineoplastic Combined Chemotherapy Protocols - therapeutic use</topic><topic>Biological and medical sciences</topic><topic>Biomedical and Life Sciences</topic><topic>Biomedicine</topic><topic>Cancer Research</topic><topic>Cancer therapies</topic><topic>Chemotherapy</topic><topic>Chemotherapy, Adjuvant</topic><topic>Clinical Study</topic><topic>Colorectal cancer</topic><topic>Colorectal Neoplasms - drug therapy</topic><topic>Colorectal Neoplasms - pathology</topic><topic>Drug Resistance</topic><topic>Epidemiology</topic><topic>Female</topic><topic>Fluorouracil - therapeutic use</topic><topic>Gastroenterology. Liver. Pancreas. Abdomen</topic><topic>Histology</topic><topic>Hospitals</topic><topic>Humans</topic><topic>Leucovorin - therapeutic use</topic><topic>Male</topic><topic>Medical research</topic><topic>Medical sciences</topic><topic>Medicine</topic><topic>Middle Aged</topic><topic>Molecular Medicine</topic><topic>Mucins - analysis</topic><topic>Mucins - metabolism</topic><topic>Multiple tumors. Solid tumors. Tumors in childhood (general aspects)</topic><topic>Neoplasm Staging</topic><topic>Oncology</topic><topic>Organoplatinum Compounds - therapeutic use</topic><topic>Patients</topic><topic>Prognosis</topic><topic>Retrospective Studies</topic><topic>Stomach. Duodenum. Small intestine. Colon. Rectum. Anus</topic><topic>Tomography</topic><topic>Tumors</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Lee, D-W</creatorcontrib><creatorcontrib>Han, S-W</creatorcontrib><creatorcontrib>Lee, H J</creatorcontrib><creatorcontrib>Rhee, Y-Y</creatorcontrib><creatorcontrib>Bae, J M</creatorcontrib><creatorcontrib>Cho, N-Y</creatorcontrib><creatorcontrib>Lee, K-H</creatorcontrib><creatorcontrib>Kim, T-Y</creatorcontrib><creatorcontrib>Oh, D-Y</creatorcontrib><creatorcontrib>Im, S-A</creatorcontrib><creatorcontrib>Bang, Y-J</creatorcontrib><creatorcontrib>Jeong, S-Y</creatorcontrib><creatorcontrib>Park, K J</creatorcontrib><creatorcontrib>Park, J-G</creatorcontrib><creatorcontrib>Kang, G H</creatorcontrib><creatorcontrib>Kim, T-Y</creatorcontrib><collection>Springer Nature OA Free Journals</collection><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Nursing & Allied Health Database</collection><collection>Oncogenes and Growth Factors Abstracts</collection><collection>Virology and AIDS Abstracts</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>ProQuest Pharma Collection</collection><collection>Public Health Database</collection><collection>ProQuest SciTech Collection</collection><collection>ProQuest Natural Science Collection</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>British Nursing Database</collection><collection>ProQuest Central Essentials</collection><collection>Biological Science Collection</collection><collection>ProQuest Central</collection><collection>Natural Science Collection</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>SciTech Premium Collection</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Nursing & Allied Health Database (Alumni Edition)</collection><collection>ProQuest Biological Science Collection</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>Biological Science Database</collection><collection>Nursing & Allied Health Premium</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>British journal of cancer</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Lee, D-W</au><au>Han, S-W</au><au>Lee, H J</au><au>Rhee, Y-Y</au><au>Bae, J M</au><au>Cho, N-Y</au><au>Lee, K-H</au><au>Kim, T-Y</au><au>Oh, D-Y</au><au>Im, S-A</au><au>Bang, Y-J</au><au>Jeong, S-Y</au><au>Park, K J</au><au>Park, J-G</au><au>Kang, G H</au><au>Kim, T-Y</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Prognostic implication of mucinous histology in colorectal cancer patients treated with adjuvant FOLFOX chemotherapy</atitle><jtitle>British journal of cancer</jtitle><stitle>Br J Cancer</stitle><addtitle>Br J Cancer</addtitle><date>2013-05-28</date><risdate>2013</risdate><volume>108</volume><issue>10</issue><spage>1978</spage><epage>1984</epage><pages>1978-1984</pages><issn>0007-0920</issn><eissn>1532-1827</eissn><coden>BJCAAI</coden><abstract>Background:
There have been controversies in prognostic impact of mucinous histology on colorectal cancer, and its implication in patients treated with adjuvant 5-fluorouracil, leucovorin, and oxaliplatin (FOLFOX) is unclear.
Methods:
Stage II and III colorectal cancer patients who underwent curative resection followed by adjuvant FOLFOX were included. Patients were grouped according to the mucinous content: >50%, mucinous adenocarcinoma (MAC); <50%, adenocarcinoma with intermediated mucinous component (AIM); and without any mucinous component, non-MAC (NMA). Clinicopathological features and disease-free survival (DFS) were compared.
Results:
Among a total of 521 patients, 27 patients (5.2%) had MAC, 41 patients (7.9%) had AIM, and 453 patients (86.9%) had NMA. Mucinous adenocarcinoma and AIM had higher frequency of proximal location and microsatellite instability, but lower frequency of angiolymphatic invasion. Disease-free survival was significantly worse in the MAC compared with NMA (3-year DFS 57% and 86%, respectively;
P
<0.001) and AIM (3-year DFS 87%,
P
=0.01
vs
MAC). Multivariate analysis revealed MAC as an independent negative prognostic factor of DFS (adjusted hazard ratio 7.96, 95% confidence interval 3.76–16.8).
Conclusion:
Adenocarcinoma with intermediated mucinous component and MAC have distinct clinicopathological features compared with NMA. Mucinous adenocarcinoma has an adverse prognostic impact on stage II or III colorectal cancer treated with adjuvant FOLFOX.</abstract><cop>London</cop><pub>Nature Publishing Group UK</pub><pmid>23652310</pmid><doi>10.1038/bjc.2013.232</doi><tpages>7</tpages><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0007-0920 |
| ispartof | British journal of cancer, 2013-05, Vol.108 (10), p.1978-1984 |
| issn | 0007-0920 1532-1827 |
| language | eng |
| recordid | cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_3670503 |
| source | MEDLINE; SpringerLink Journals; Nature Journals Online; Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals; PubMed Central |
| subjects | 692/699/67/1059/99 692/699/67/1504/1885 692/700/1750 Adenocarcinoma, Mucinous - drug therapy Adenocarcinoma, Mucinous - pathology Adult Aged Aged, 80 and over Antineoplastic Combined Chemotherapy Protocols - therapeutic use Biological and medical sciences Biomedical and Life Sciences Biomedicine Cancer Research Cancer therapies Chemotherapy Chemotherapy, Adjuvant Clinical Study Colorectal cancer Colorectal Neoplasms - drug therapy Colorectal Neoplasms - pathology Drug Resistance Epidemiology Female Fluorouracil - therapeutic use Gastroenterology. Liver. Pancreas. Abdomen Histology Hospitals Humans Leucovorin - therapeutic use Male Medical research Medical sciences Medicine Middle Aged Molecular Medicine Mucins - analysis Mucins - metabolism Multiple tumors. Solid tumors. Tumors in childhood (general aspects) Neoplasm Staging Oncology Organoplatinum Compounds - therapeutic use Patients Prognosis Retrospective Studies Stomach. Duodenum. Small intestine. Colon. Rectum. Anus Tomography Tumors |
| title | Prognostic implication of mucinous histology in colorectal cancer patients treated with adjuvant FOLFOX chemotherapy |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-14T10%3A22%3A53IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Prognostic%20implication%20of%20mucinous%20histology%20in%20colorectal%20cancer%20patients%20treated%20with%20adjuvant%20FOLFOX%20chemotherapy&rft.jtitle=British%20journal%20of%20cancer&rft.au=Lee,%20D-W&rft.date=2013-05-28&rft.volume=108&rft.issue=10&rft.spage=1978&rft.epage=1984&rft.pages=1978-1984&rft.issn=0007-0920&rft.eissn=1532-1827&rft.coden=BJCAAI&rft_id=info:doi/10.1038/bjc.2013.232&rft_dat=%3Cproquest_pubme%3E2981885311%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1355893064&rft_id=info:pmid/23652310&rfr_iscdi=true |